Diagnostics Firm Penalized by SEC for Allegedly Misleading Press Releases About a COVID-19 Test

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Diagnostics Firm Penalized by SEC for Allegedly Misleading Press Releases About a COVID-19 Test

Co-Diagnostics Also Allegedly Failed To Report Transactions With Company Officials’ Family Members

Dennis Tosh

July 12, 2023 at 08:00 PM EST

Utah-based Co-Diagnostics Inc., a developer of molecular tools for the detection of infectious diseases, was ordered to pay the Securities and Exchange Commission (SEC) $250,000 to resolve allegations that the company violated commission requirements by issuing misleading press releases in February 2020 concerning a test for detecting the virus that causes COVID-19 and by not ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Diagnostics Firm Penalized by SEC for Allegedly Misleading Press Releases About a COVID-19 Test

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT